Results 91 to 100 of about 35,001 (246)

The Clinical Efficacy of High‐Voltage Long‐Duration Pulsed Radiofrequency Treatment in Pudendal Neuralgia: A Retrospective Study

Neuromodulation: Technology at the Neural Interface, EarlyView., 2021
Abstract Background Patients with pudendal neuralgia (PN) experience long‐lasting chronic pain, hyperalgesia, and comorbid emotional disorders, such as depression and anxiety. Treatment via conventional pulsed radiofrequency (PRF) current carries a significantly high rate of failure.
Cheng‐Long Wang, Tao Song
wiley   +1 more source

Single‐dose enflicoxib versus a 7‐day course of firocoxib for postoperative pain control in dogs undergoing orthopaedic surgery: A multicentre, randomised, masked, non‐inferiority study

Veterinary Record, EarlyView.
Abstract Background Perioperative analgesia is essential in dogs undergoing orthopaedic surgery, and enflicoxib's long duration makes single‐dose administration attractive. Methods A prospective, multicentre, randomised, masked trial compared enflicoxib (8 mg/kg) given 24 hours before surgery with firocoxib (5 mg/kg) given daily for 7 days. Two hundred
Marta Salichs, José I. Redondo, Anabel Blasco‐Moreno, Llorenç Badiella, Josep Homedes   +4 more
wiley   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source

Factors Associated With Non‐Vasomotor Menopause Symptoms Experienced by 7285 Women: A UK‐Wide National Survey

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To investigate the factors associated with non‐vasomotor menopause symptoms among women in the UK, focusing on the perceived importance of specific symptoms and their association with demographic and treatment‐related factors. Design A cross‐sectional online survey.
Rhianna Davies, Ashwin Goyal, Zachary Nash, Sarah Hillman, Melanie Davies, Nick Panay, Jane Daniels, Tim Hillard, Bonnie Grant, Paula Briggs, Lynne Robinson, Haitham Hamoda, Channa N. Jayasena   +12 more
wiley   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Benzodiazepine Use and Mortality Risk: A Nationwide Cohort Study on New Benzodiazepine Users With a 5‐Year Follow‐Up

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction We aimed to investigate the risks of all‐cause and cause‐specific mortality associated with dose‐dependent benzodiazepine and Z‐drug (BZDR) use in the Finnish population initiating new BZDR use with five‐year follow‐up. Methods Study subjects were included if BZDR use had started in 2006 with no BZDR dispensing during the ...
Hanna Särkilä, Heidi Taipale, Antti Tanskanen, Tero Taiminen, Reijo Sund, Terhi Kurko, Jarmo Hietala, Solja Niemelä   +7 more
wiley   +1 more source

5‐Methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder formulation of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT) benzoate salt, in people with moderate–severe AUD enrolled in a standard of care, 10‐week programme of relapse‐prevention oriented Cognitive ...
John Marsden, Michael Kelleher, Fiona Dunbar, Anna O. Ermakova, Luke Mitcheson, Claire Roberts, James J. Rucker, Gemma Scott, Ivan Saeger, Francesca Small, Mathieu Seynaeve   +10 more
wiley   +1 more source

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

A Case Report of Gabapentin-induced Psychotic Disorder

Journal of Mazandaran University of Medical Sciences, 2018
Gabapentin was first approved for treatment of epilepsy by FDA, but later it received more attention due to its effects on pain relief, especially neuropathic pain and post-herpetic neuralgia, and in treatment of anxiety and insomnia.
Pezhman Hadinezhad, Hamzeh Hosseini
doaj